Aurora Cannabis (TSX:ACB) Keeps Burning Cash as Revenue Falls

Aurora Cannabis (TSX:ACB)(NASDAQ:ACB) is still losing money. Its revenue is declining, too.

| More on:
A cannabis plant grows.

Source: Getty Images

Aurora Cannabis (TSX:ACB)(NASDAQ:ACB) stock got some attention recently when it rallied 31% over the course of a week. The stock’s rally took place between July 11 and July 20. It wasn’t the first time that Aurora gained so much in a short time frame, but it was notable for when it happened. Cannabis stocks got a brief jolt of life last month when the U.S. Senate floated the idea of legalizing cannabis. U.S. legalization is thought to be the next big catalyst for cannabis producers, as it could open a legal market 10 times the size of Canada.

It could be that Aurora Cannabis would get a boost from cannabis being legalized in the United States. It would certainly provide the potential for new revenue. Today, though, the company is struggling. Its revenue is down some 11% over the last year, and its losses are growing. ACB hasn’t managed to differentiate itself from other cannabis companies in the post-legalization era, and it’s starting to show.

Why revenue is falling

In its most recent quarter, Aurora’s revenue fell 9% and it lost $12.2 million. The loss shrank on a year-over-year basis but was still large as a percentage of revenue. The decline in revenue was mainly due to the consumer segment, which shrank nearly 40%. The company attributed the lower consumer sales to pricing pressure.

There are many players in the Canadian cannabis space, and their products are all pretty similar. As a result, they compete on price in a market that’s not exactly growing a whole lot, so their sales tend to fall over time. Medical sales tend to be a little better, since medical cannabis is more regulated and is more frequently sold in jurisdictions where recreational cannabis isn’t legal.

Still losing money

As mentioned previously, Aurora Cannabis was still losing money in its most recent quarter. The loss declined as a percentage of revenue but was still fairly large. In Q3, Aurora’s loss was $12.2 million, and sales were $50 million. So, we’ve got a loss that’s about $24.4% of revenue. It won’t be easy to turn that into a profit. Aurora says that it should be profitable by the first half of 2023, but we’re pretty close to 2023 already, and profits are nowhere in sight.

The company’s third-quarter press release says that $150-$170 million in cost savings will fuel the move toward profitability. That may be the case, but what if sales keep declining? Aurora itself admits that it’s facing a lot of price pressure, so it looks like the decline in sales could continue. If it does, then losses could rise.

Foolish takeaway

Aurora Cannabis stock will occasionally get a boost when rumours of U.S. cannabis legalization start to circulate. As we saw last month, it only takes talk of legalization for ACB to rise. Like many mid-cap stocks, it can rally due to a something as small as a rumour. That doesn’t mean that U.S. legalization will actually save Aurora, though. Maybe ACB would do more sales if the U.S. legalized cannabis, but it wouldn’t necessarily become profitable. There’s too much competition in its industry for high margins to be achieved.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Button has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

2 Cannabis Stocks I’d Buy Over Canopy Growth

Here's why these two cannabis stocks are better long-term investments compared to Canopy Growth stock in 2023.

Read more »

edit Jars of marijuana
Cannabis Stocks

A Dividend Giant I’d Buy Over Canopy Growth Stock

Forget investing in a fundamentally weak stock such as Canopy Growth and buy shares of this cannabis REIT instead.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Canopy Growth Corp: The Bottom Isn’t In

Canopy Growth Corp (TSX:WEED) is hitting new lows. Unfortunately, the bottom probably isn't in.

Read more »

edit Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.
Cannabis Stocks

Is Canopy Growth Stock a Buy in September?

Canopy Growth stock (TSX:WEED) has seen some major movement recently, with good news from the US boosting it further.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Will Canopy Growth Stock Continue to Surge in September 2023?

Canopy Growth stock has surged over 70% in the past week. Is WEED stock a good buy right now?

Read more »

A cannabis plant grows.
Cannabis Stocks

Is Canopy Growth Stock Worth a Buy in September?

Here's the bull and bear case behind whether Canopy Growth (TSX:WEED) stock is worth a speculative buy in September or…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Why Cannabis Stocks Are Flying Higher Again Today

Here’s why cannabis stocks, including TLRY, CRON, and ACB, are skyrocketing this week.

Read more »

A cannabis plant grows.
Cannabis Stocks

If You’d Invested $10,000 in Canopy Growth Stock When Cannabis Became Legal, Here’s What You’d Be Left with Today

A large investment in Canopy Growth Corp. (TSX:WEED) when cannabis was legalized may have seemed like a good idea at…

Read more »